Matches in SemOpenAlex for { <https://semopenalex.org/work/W3215739139> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W3215739139 abstract "<b>Background:</b> New therapies are needed to target vascular remodeling in PAH. Sotatercept is a novel first-in-class fusion protein that acts by rebalancing deficient BMPR2 signaling. <b>Aims and Objectives:</b> To determine the safety and efficacy of sotatercept for the treatment of PAH. <b>Methods:</b> 106 WHO Group 1 PAH patients (pts) were enrolled: WHO functional class (FC)II-III; baseline pulmonary vascular resistance of ≥5 Wood units; 6MWD of 150-550m. Sotatercept (0.3mg/kg or 0.7mg/kg) was added to standard of care (SOC) for a 24-week (wk) double-blind, placebo-controlled treatment period. The extension period is ongoing in which sotatercept-treated pts maintain their current dose level, and placebo-treated pts were re-randomized to 0.3mg/kg or 0.7mg/kg sotatercept. <b>Results:</b> Continuation of sotatercept treatment for up to 48 wks maintained the improvements observed in 6MWD, NT-proBNP, and change in WHO FC at 24 weeks versus baseline. Pts re-randomized from placebo to sotatercept showed improvements in 6MWD, NT-proBNP, and change in WHO FC at 48 wks compared to 24 wks and baseline. Cumulatively during the trial, 30/106(28.3%) patients reported serious treatment-emergent adverse events (TEAEs), 9(8.5%) TEAEs led to study discontinuation, and 2(1.9%) TEAEs led to death. <b>Conclusions:</b> Continued sotatercept treatment maintained clinical efficacy across multiple study endpoints for up to 48 wks. Importantly, placebo assignment did not affect the ability to respond after 24 wks. Safety was consistent with previous reports in PAH and other pt populations." @default.
- W3215739139 created "2021-12-06" @default.
- W3215739139 creator A5005171363 @default.
- W3215739139 creator A5006873131 @default.
- W3215739139 creator A5010237095 @default.
- W3215739139 creator A5015138889 @default.
- W3215739139 creator A5016773092 @default.
- W3215739139 creator A5021150751 @default.
- W3215739139 creator A5022727833 @default.
- W3215739139 creator A5025271649 @default.
- W3215739139 creator A5035496455 @default.
- W3215739139 creator A5037889523 @default.
- W3215739139 creator A5056518661 @default.
- W3215739139 creator A5056570032 @default.
- W3215739139 date "2021-09-05" @default.
- W3215739139 modified "2023-09-27" @default.
- W3215739139 title "PULSAR open-label extension: interim results from a phase 2 study of the efficacy and safety of sotatercept when added to standard of care for the treatment of pulmonary arterial hypertension (PAH)" @default.
- W3215739139 doi "https://doi.org/10.1183/13993003.congress-2021.oa140" @default.
- W3215739139 hasPublicationYear "2021" @default.
- W3215739139 type Work @default.
- W3215739139 sameAs 3215739139 @default.
- W3215739139 citedByCount "0" @default.
- W3215739139 crossrefType "proceedings-article" @default.
- W3215739139 hasAuthorship W3215739139A5005171363 @default.
- W3215739139 hasAuthorship W3215739139A5006873131 @default.
- W3215739139 hasAuthorship W3215739139A5010237095 @default.
- W3215739139 hasAuthorship W3215739139A5015138889 @default.
- W3215739139 hasAuthorship W3215739139A5016773092 @default.
- W3215739139 hasAuthorship W3215739139A5021150751 @default.
- W3215739139 hasAuthorship W3215739139A5022727833 @default.
- W3215739139 hasAuthorship W3215739139A5025271649 @default.
- W3215739139 hasAuthorship W3215739139A5035496455 @default.
- W3215739139 hasAuthorship W3215739139A5037889523 @default.
- W3215739139 hasAuthorship W3215739139A5056518661 @default.
- W3215739139 hasAuthorship W3215739139A5056570032 @default.
- W3215739139 hasConcept C126322002 @default.
- W3215739139 hasConcept C142724271 @default.
- W3215739139 hasConcept C166957645 @default.
- W3215739139 hasConcept C168563851 @default.
- W3215739139 hasConcept C197934379 @default.
- W3215739139 hasConcept C204787440 @default.
- W3215739139 hasConcept C27081682 @default.
- W3215739139 hasConcept C2776957806 @default.
- W3215739139 hasConcept C2778375690 @default.
- W3215739139 hasConcept C2778715236 @default.
- W3215739139 hasConcept C61943457 @default.
- W3215739139 hasConcept C71924100 @default.
- W3215739139 hasConcept C95457728 @default.
- W3215739139 hasConceptScore W3215739139C126322002 @default.
- W3215739139 hasConceptScore W3215739139C142724271 @default.
- W3215739139 hasConceptScore W3215739139C166957645 @default.
- W3215739139 hasConceptScore W3215739139C168563851 @default.
- W3215739139 hasConceptScore W3215739139C197934379 @default.
- W3215739139 hasConceptScore W3215739139C204787440 @default.
- W3215739139 hasConceptScore W3215739139C27081682 @default.
- W3215739139 hasConceptScore W3215739139C2776957806 @default.
- W3215739139 hasConceptScore W3215739139C2778375690 @default.
- W3215739139 hasConceptScore W3215739139C2778715236 @default.
- W3215739139 hasConceptScore W3215739139C61943457 @default.
- W3215739139 hasConceptScore W3215739139C71924100 @default.
- W3215739139 hasConceptScore W3215739139C95457728 @default.
- W3215739139 hasLocation W32157391391 @default.
- W3215739139 hasOpenAccess W3215739139 @default.
- W3215739139 hasPrimaryLocation W32157391391 @default.
- W3215739139 hasRelatedWork W137885780 @default.
- W3215739139 hasRelatedWork W1966047811 @default.
- W3215739139 hasRelatedWork W2003042623 @default.
- W3215739139 hasRelatedWork W202460821 @default.
- W3215739139 hasRelatedWork W2030348591 @default.
- W3215739139 hasRelatedWork W2145101709 @default.
- W3215739139 hasRelatedWork W2792428998 @default.
- W3215739139 hasRelatedWork W2996750011 @default.
- W3215739139 hasRelatedWork W3023502736 @default.
- W3215739139 hasRelatedWork W4223500234 @default.
- W3215739139 isParatext "false" @default.
- W3215739139 isRetracted "false" @default.
- W3215739139 magId "3215739139" @default.
- W3215739139 workType "article" @default.